ArticleThoracic cancer2019

Larger tumors are associated with inferior progression-free survival of first-line EGFR-tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non-small cell lung cancer.

Yingying Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.